Last reviewed · How we verify
Lantus (INSULIN GLARGINE)
Lantus works by mimicking the action of natural insulin to lower blood sugar levels.
Lantus (INSULIN GLARGINE) is a long-acting insulin analog developed by Sanofi Aventis US, targeting the insulin receptor to regulate blood glucose levels. It is used to treat both type 1 and type 2 diabetes mellitus. Lantus is a patented small molecule insulin, FDA-approved in 2000, and is still commercially available under the brand name. Key safety considerations include the risk of hypoglycemia, weight gain, and potential increased risk of cardiovascular events. As a long-acting insulin, it provides a steady glucose-lowering effect over 24 hours.
At a glance
| Generic name | INSULIN GLARGINE |
|---|---|
| Sponsor | Sanofi |
| Drug class | Insulin Analog [EPC] |
| Target | Insulin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2000 |
| Annual revenue | 4800 |
Mechanism of action
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Approved indications
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
- Severe symptomatic hypoglycemia
- Edema peripheral
- Hypertension
- Influenza
- Sinusitis
- Cataract
- Bronchitis
- Arthralgia
- Pain in extremity
- Back pain
- Cough
- Urinary tract infection
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |